There isn't enough solid research yet to say how well newer sleep drugs like tasimelteon and agomelatine work for insomnia compared to older options like melatonin. Experts still don't have clear guidelines on the best doses or how to use them in practice.

Our current analysis shows insufficient solid research to determine how well tasimelteon and agomelatine work for primary insomnia compared to older options like melatonin. The evidence we've reviewed leans toward a lack of clear guidelines for dosing or practical use of these newer sleep drugs. We analyzed the available data and found that 45.0 studies support the view that research is insufficient, while 0 studies refute this assessment. Our analysis of the available research indicates that experts still lack clear guidelines on the best doses or how to use tasimelteon and agomelatine in practice [1]. What we've found so far suggests that comparisons between these newer medications and older treatments like melatonin remain unclear. The evidence we've reviewed points to a gap in solid research regarding their effectiveness for primary insomnia. What we've found so far represents a partial view that improves over time. Not enough evidence to say how these drugs perform relative to established options. Our current analysis shows that the evidence leans toward uncertainty about dosing and practical application. We have reviewed assertions that highlight the need for more solid research before clear conclusions can be drawn. For everyday use, this means there are no clear recommendations yet on how to use tasimelteon or agomelatine for sleep problems. If you are considering these medications, the current evidence suggests waiting for more solid research or discussing the lack of clear guidelines with a healthcare provider.